Mark S. Shaefer

3.6k total citations
79 papers, 2.4k citations indexed

About

Mark S. Shaefer is a scholar working on Infectious Diseases, Virology and Pharmacology. According to data from OpenAlex, Mark S. Shaefer has authored 79 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Infectious Diseases, 38 papers in Virology and 14 papers in Pharmacology. Recurrent topics in Mark S. Shaefer's work include HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (38 papers) and HIV/AIDS Research and Interventions (33 papers). Mark S. Shaefer is often cited by papers focused on HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (38 papers) and HIV/AIDS Research and Interventions (33 papers). Mark S. Shaefer collaborates with scholars based in United States, United Kingdom and Canada. Mark S. Shaefer's co-authors include Paul Wannamaker, Lisa Ross, Denise Sutherland‐Phillips, Qiming Liao, Edwin DeJesus, Benjamin Young, Cindy Vavro, Philip Lackey, Linda Yau and Nicholaos Bellos and has published in prestigious journals such as The Lancet, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Mark S. Shaefer

79 papers receiving 2.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark S. Shaefer 1.5k 1.1k 438 419 379 79 2.4k
Jennifer J. Kiser 2.5k 1.7× 1.1k 1.0× 403 0.9× 1.3k 3.1× 100 0.3× 107 3.5k
Cristina Gervasoni 1.4k 0.9× 601 0.6× 619 1.4× 578 1.4× 128 0.3× 132 2.1k
Brian P. Kearney 3.9k 2.7× 2.4k 2.3× 843 1.9× 1.1k 2.7× 88 0.2× 93 5.1k
Daniel Podzamczer 3.3k 2.2× 2.4k 2.3× 1.5k 3.3× 726 1.7× 106 0.3× 144 4.0k
R. Garraffo 555 0.4× 359 0.3× 129 0.3× 313 0.7× 340 0.9× 92 1.3k
Brian Wynne 2.0k 1.3× 1.4k 1.4× 617 1.4× 651 1.6× 107 0.3× 70 2.6k
Janez Tomažič 542 0.4× 334 0.3× 151 0.3× 323 0.8× 560 1.5× 51 1.7k
Laura Waters 1.6k 1.1× 936 0.9× 798 1.8× 472 1.1× 90 0.2× 96 2.2k
Geoffrey J. Yuen 1.0k 0.7× 629 0.6× 123 0.3× 416 1.0× 116 0.3× 39 1.5k
Joaquin Valdes 1.1k 0.7× 887 0.8× 280 0.6× 453 1.1× 54 0.1× 31 2.6k

Countries citing papers authored by Mark S. Shaefer

Since Specialization
Citations

This map shows the geographic impact of Mark S. Shaefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Shaefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Shaefer more than expected).

Fields of papers citing papers by Mark S. Shaefer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Shaefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Shaefer. The network helps show where Mark S. Shaefer may publish in the future.

Co-authorship network of co-authors of Mark S. Shaefer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Shaefer. A scholar is included among the top collaborators of Mark S. Shaefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Shaefer. Mark S. Shaefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mounzer, Karam, Jennifer S Fusco, Laurence Brunet, et al.. (2021). Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. AIDS Patient Care and STDs. 35(11). 419–427. 7 indexed citations
2.
Mounzer, Karam, Ricky Hsu, Jennifer S Fusco, et al.. (2019). HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. AIDS Research and Therapy. 16(1). 1–1. 38 indexed citations
3.
4.
Ross, Lisa, Denise Shortino, & Mark S. Shaefer. (2018). Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States. AIDS Research and Human Retroviruses. 34(8). 672–679. 20 indexed citations
5.
Squires, Kathleen, Benjamin Young, Lizette Santiago, et al.. (2017). Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV/AIDS - Research and Palliative Care. Volume 9. 51–61. 5 indexed citations
6.
7.
Wohl, David A., Laveeza Bhatti, Catherine B. Small, et al.. (2014). Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial. PLoS ONE. 9(5). e96187–e96187. 16 indexed citations
8.
Shaefer, Mark S., et al.. (2012). Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1–Infected Patients With or Without Hepatitis B or C Coinfection. HIV Clinical Trials. 13(3). 171–177. 6 indexed citations
9.
10.
Squires, Kathleen, Benjamin Young, Edwin DeJesus, et al.. (2012). ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. HIV Clinical Trials. 13(5). 233–244. 21 indexed citations
11.
Watson, Maria, Lisa Patel, Belinda Ha, et al.. (2009). A Study of HIV Provider Attitudes Toward HLA-B*5701 Testing in the United States. AIDS Patient Care and STDs. 23(11). 957–963. 3 indexed citations
12.
Saag, Michael S., Ramani Balu, Philip S. Brachman, et al.. (2007). High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR). Murdoch Research Repository (Murdoch University). 115(2). 163–5. 8 indexed citations
13.
14.
Rawlings, M. Keith, Melanie Thompson, Charles Farthing, et al.. (2003). Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 34(2). 174–183. 64 indexed citations
15.
Liao, Qiming, et al.. (2002). Genotypic and Phenotypic Cross-Resistance Patterns to Lopinavir and Amprenavir in Protease Inhibitor-Experienced Patients with HIV Viremia. AIDS Research and Human Retroviruses. 18(14). 1011–1019. 21 indexed citations
16.
Jusko, William J., Wojciech Piekoszewski, Göran B. Klintmalm, et al.. (1995). Pharmacokinetics of tacrolimus in liver transplant patients*. Clinical Pharmacology & Therapeutics. 57(3). 281–290. 204 indexed citations
17.
Stratta, Robert J., Mark S. Shaefer, Rodney S. Markin, et al.. (1991). Ganciclovir therapy for viral disease in liver transplant recipients. Clinical Transplantation. 5(4). 287–293. 12 indexed citations
18.
Shaefer, Mark S., et al.. (1990). Sensory/Mixability Preference Evaluation of Cholestyramine Powder Formulations. DICP. 24(5). 472–474. 3 indexed citations
19.
Shaefer, Mark S., et al.. (1990). Drug-Induced Hypertrichosis: Case Report and Review of the Literature. DICP. 24(4). 365–368. 10 indexed citations
20.
Shaefer, Mark S., et al.. (1989). Prolonged Paralysis Associated with Long‐Term Pancuronium Use. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 9(3). 154–157. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer J. Kiser Breakdown of academic impact, for papers by Cristina Gervasoni Breakdown of academic impact, for papers by Brian P. Kearney Breakdown of academic impact, for papers by Daniel Podzamczer Breakdown of academic impact, for papers by R. Garraffo Breakdown of academic impact, for papers by Brian Wynne Breakdown of academic impact, for papers by Janez Tomažič Breakdown of academic impact, for papers by Laura Waters Breakdown of academic impact, for papers by Geoffrey J. Yuen Breakdown of academic impact, for papers by Joaquin Valdes
Rankless by CCL
2026